NDC 64679-794

Imatinib Mesylate

Imatinib Mesylate

Imatinib Mesylate is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Wockhardt Usa Llc.. The primary component is Imatinib Mesylate.

Product ID64679-794_016beab4-925a-4cb0-b994-cd0ba0419879
NDC64679-794
Product TypeHuman Prescription Drug
Proprietary NameImatinib Mesylate
Generic NameImatinib Mesylate
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2019-01-17
Marketing CategoryANDA / ANDA
Application NumberANDA208429
Labeler NameWockhardt USA LLC.
Substance NameIMATINIB MESYLATE
Active Ingredient Strength400 mg/1
Pharm ClassesKinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 64679-794-01

30 TABLET in 1 BOTTLE (64679-794-01)
Marketing Start Date2019-01-17
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 64679-794-03 [64679079403]

Imatinib Mesylate TABLET
Marketing CategoryANDA
Application NumberANDA208429
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-17

NDC 64679-794-01 [64679079401]

Imatinib Mesylate TABLET
Marketing CategoryANDA
Application NumberANDA208429
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-17

NDC 64679-794-02 [64679079402]

Imatinib Mesylate TABLET
Marketing CategoryANDA
Application NumberANDA208429
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-17

Drug Details

Active Ingredients

IngredientStrength
IMATINIB MESYLATE400 mg/1

OpenFDA Data

SPL SET ID:7fd8afed-3bb5-4029-a347-665e032d56e6
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 403878
  • 403879
  • UPC Code
  • 0364679794012
  • Pharmacological Class

    • Kinase Inhibitor [EPC]
    • Protein Kinase Inhibitors [MoA]
    • Kinase Inhibitor [EPC]
    • Protein Kinase Inhibitors [MoA]

    NDC Crossover Matching brand name "Imatinib Mesylate" or generic name "Imatinib Mesylate"

    NDCBrand NameGeneric Name
    0054-0248Imatinib MesylateImatinib Mesylate
    0054-0249Imatinib MesylateImatinib Mesylate
    0093-7629Imatinib MesylateImatinib Mesylate
    0093-7630Imatinib MesylateImatinib Mesylate
    0378-2245Imatinib Mesylateimatinib
    0378-2246Imatinib Mesylateimatinib
    0904-6621Imatinib MesylateImatinib Mesylate
    67877-634Imatinib mesylateImatinib mesylate
    67877-633Imatinib mesylateImatinib mesylate
    72485-202Imatinib mesylateImatinib mesylate
    0904-6901Imatinib MesylateImatinib Mesylate
    16714-704imatinib mesylateimatinib mesylate
    16714-705imatinib mesylateimatinib mesylate
    42292-044Imatinib MesylateImatinib Mesylate
    42292-043Imatinib MesylateImatinib Mesylate
    47335-472imatinib mesylateimatinib mesylate
    47335-475imatinib mesylateimatinib mesylate
    50268-426Imatinib MesylateImatinib Mesylate
    50268-427Imatinib MesylateImatinib Mesylate
    51991-376IMATINIB MESYLATEIMATINIB MESYLATE
    51991-377IMATINIB MESYLATEIMATINIB MESYLATE
    60429-926Imatinib MesylateImatinib Mesylate
    60505-2900Imatinib MesylateImatinib Mesylate
    60429-925Imatinib MesylateImatinib Mesylate
    60687-203Imatinib MesylateImatinib Mesylate
    60505-2901Imatinib MesylateImatinib Mesylate
    60687-192Imatinib MesylateImatinib Mesylate
    64679-794Imatinib MesylateImatinib Mesylate
    64679-793Imatinib MesylateImatinib Mesylate
    65162-795Imatinib MesylateImatinib Mesylate
    65162-794Imatinib MesylateImatinib Mesylate
    68180-390IMATINIB MESYLATEIMATINIB MESYLATE
    68180-391IMATINIB MESYLATEIMATINIB MESYLATE
    51407-270Imatinib MesylateImatinib Mesylate
    51407-269Imatinib MesylateImatinib Mesylate
    72606-556Imatinib mesylateImatinib mesylate
    72606-557Imatinib mesylateImatinib mesylate
    0078-0401Gleevecimatinib mesylate
    0078-0649Gleevecimatinib mesylate

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.